Global Women’s Health Market, By Drugs (Prolia, XGEVA, EVISTA, Mirena, Zometa, Reclast or Aclasta, Minastrin 24 Fe, FORTEO, NuvaRing, Primarin, ACTONEL, ORTHO TRI-CY LO (28)), Application (Hormonal Infertility, Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, Polycystic Ovary Syndrome (PCOS), Menopause, Other Applications) - Industry Trends and Forecast to 2030.
Women’s Health Market Analysis and Size
Women's health refers to the health of women, which differs from that of men in many ways. Women's health is important because it affects not only women but also their families and society as a whole. In medicine, known as women’s health disorders that impact a woman’s physical and psychological health are treated and diagnosed. It includes all procedures, medications, and surgical supplies for disorders affecting the group of women. Women experience different biological, social, and behavioral factors than males, which affect their health and disease in different ways. The biological variations range from phenotypic to cellular biology and exhibit specific risks for disease emergence. Nutrition, cancer, reproduction, menopause, urology, and other areas of healthcare are among these illnesses. Women’s health is concerned with providing better illness management and boosting or improving the general health of the female population.
Data Bridge Market Research analyses that the global women’s health market which was USD 4,000.00 million in 2022, would rocket up to USD 6,200.00 million by 2030, and is expected to undergo a CAGR of 5.5% during the forecast period. This indicates the market value. Hormonal Infertility is expected to dominate the application segment of the Women’s Health market owing to the growing demand for women's health check-ups. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Women’s Health Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015-2020)
Revenue in USD Million, Volumes in Units, and Pricing in USD
Drugs (Prolia, XGEVA, EVISTA, Mirena, Zometa, Reclast or Aclasta, Minastrin 24 Fe, FORTEO, NuvaRing, Primarin, ACTONEL, ORTHO TRI-CY LO (28)), Application (Hormonal Infertility, Female Infertility, postmenopausal Osteoporosis, Endometriosis, Contraception, Polycystic Ovary Syndrome (PCOS), Menopause, Other Applications)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Siemens (Germany), Hologic, Inc. (U.S.), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), Abbott (U.S.), BD (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), NeuroLogica Corp. (U.S.), Shimadzu Medical (India) pvt. Ltd. (Japan), GENERAL ELECTRIC (U.S.), Quest Diagnostics Incorporated (U.S.), Sysmex India Pvt. Ltd. (Japan), Hitachi, Ltd. (Japan), Canon Inc. (Japan), FUJIFILM Holdings Corporation (U.K.) among others
Women's health includes treatments, medications, surgical procedures, and preventative measures for the female population's various ailments. These conditions may be distinct from those treated in urology, nutrition, cancer, reproductive, menopause, and other medical specialties. Women's health is focused on providing for improved disease management and boosting the general health of the female population.
Global Women’s Health Market Dynamics
- Growing Prevalence of women’s biological issues
The women’s healthcare market is concentrated on women’s health problems. The market deals with issues such as pregnancy, menopause, breast cancer, and conditions related to reproductive organs. The growing biological issues in women's also driving the market growth, According to World Health Organization (WHO), breast cancer is frequently occurring among women, affecting 2.1 Billion women every year, and about 15% of all women's deaths are due to breast cancer.
The most common disease in the globe as of the end of 2020 was breast cancer, which had been diagnosed in 7.8 billion women in the previous five years. Worldwide, breast cancer causes more lost disability-adjusted life years (DALYs) for women than any other kind of cancer. Every country in the globe experiences breast cancer in women after puberty at any age, albeit the incidence rates rise as people age. Therefore, such medical condition related to women’s health has enhanced the market
- Research and development proficiencies
Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to medical drugs will further create lucrative market growth opportunities. Research and development proficiencies being conducted to develop medical instruments is also expected to drive the market growth rate.
- Development of new medicines
The growth in the number of women over 60 who adopt unhealthy lifestyle habits and the development of new medicines specifically for women are the main drivers of the global women's health market. Numerous illnesses affect women, including osteoporosis, osteoarthritis, anemia, abnormalities of menstrual health, depression, and obesity. Therefore, the market expansion in the upcoming years is projected to be boosted by these rising illnesses.
Furthermore, an upsurge in the public-private funding for target research activities, rising demand for eye diseases treatments using advanced drugs, and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2023 to 2030 Additionally, the rising internet penetration rate, increasing adoption of digital devices, rise in the elderly and obese population globally, and increasing per capita expenditure on health care will further expand the market's growth rate in the future.
On the other hand, high costs associated with research and development proficiencies, limited infrastructural facilities, high costs associated with women's medicine, and a dearth of awareness in backward economies are expected to obstruct market growth. Also, the lack of favorable reimbursement scenarios and technology penetration in developing economies, the heavy customs duty imposed on medical devices, and the lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2023-2030.
This global women’s health market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Women’s Health market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
- In December 2020, Pfizer, Inc. collaborated with Myovant Sciences for the commercialization and development of Relugolix which is the first and only oral GnRH antagonist for oncology and women’s health
- In September 2020, Bayer expanded its woman's healthcare product portfolio with the acquisition of KaNDy Therapeutics Ltd.
Global Women’s Health Market Scope
The global women’s health market is segmented on the basis of drugs and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Reclast or Aclasta
- Minastrin 24 Fe
- ORTHO TRI-CY LO (28)
- Hormonal Infertility
- Female Infertility
- Postmenopausal Osteoporosis
- Polycystic Ovary Syndrome (PCOS)
Global Women’s Health Market Regional Analysis/Insights
The global Women’s Health market is analysed and market size insights and trends are provided by country, drug and application as referenced above.
The countries covered in the global women’s health market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the global women’s health market because of the strong base of testing facilities, the strong presence of major players in the market increases cases of women's disorders, and the rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, growing research activities in the region, availability of massive untapped markets, a large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global women’s health market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the global women’s health market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the global women’s health market. The data is available for the historic period 2015-2020.
Competitive Landscape and Women’s Health Market Share Analysis
The global women’s health market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global women’s health market.
Some of the major players operating in the global women’s health market are:
- Siemens (Germany)
- Hologic, Inc. (U.S.)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- Abbott (U.S.)
- BD (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- NeuroLogica Corp. (U.S.)
- Shimadzu Medical pvt. Ltd. (Japan)
- GENERAL ELECTRIC (U.S.)
- Quest Diagnostics Incorporated (U.S.)
- Sysmex India Pvt. Ltd. (Japan)
- Hitachi, Ltd. (Japan)
- Canon Inc. (Japan)
- FUJIFILM Holdings Corporation (U.K.)